Breaking News Instant updates and real-time market news.

PFE

Pfizer

$39.37

-0.5 (-1.25%)

, LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

17:07
04/18/19
04/18
17:07
04/18/19
17:07

Pfizer, Lilly say tanezumab met 2/3 co-primary endpoints in Phase 3 study

Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs in patients with moderate-to-severe osteoarthritis of the hip or knee. The tanezumab 5 mg treatment arm met two of the three co-primary efficacy endpoints, demonstrating a statistically significant improvement in pain and physical function compared to NSAIDs at the 16-week analysis, while patients' overall assessment of their OA was not statistically different than NSAIDs. Patients who received tanezumab 2.5 mg did not experience a statistically significant improvement in pain, physical function or patients' overall assessment of their OA at 16 weeks compared to NSAIDs. In the safety analysis, there was a higher rate of joint safety events in the tanezumab arms compared to NSAIDs at 80 weeks; the difference was statistically significant. Joint safety was a composite measure consisting of adjudicated outcomes of rapidly progressive osteoarthritis type 1 or type 2, subchondral insufficiency fracture, osteonecrosis or pathological fracture. Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor inhibitors. "We are analyzing these findings in the context of the recent Phase 3 results as we assess potential next steps for tanezumab," said Ken Verburg, tanezumab development team leader, Pfizer Global Product Development. "We plan to review the totality of data from our clinical development program for tanezumab with regulatory authorities."

PFE

Pfizer

$39.37

-0.5 (-1.25%)

LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 30

    Apr

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

PFE Pfizer
$39.37

-0.5 (-1.25%)

01/31/19
01/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Tiffany (TIF) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying the pullback has been largely driven by macro concerns while fundamentals of the brand are strong and preliminary FY19 guidance is conservative. 3. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. Geron (GERN) upgraded to Buy from Neutral at B. Riley FBR with analyst George Zavoico saying he believes investors should focus on the pivotal Phase III trial of imetelstat. 5. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's improving sakes, combined with ongoing margin expansion, should bolster its earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/19
SBSH
02/20/19
UPGRADE
Target $41
SBSH
Neutral
Pfizer resumed with a Neutral from Sell at Citi
Citi analyst Andrew Baum resumed coverage of Pfizer following a period of restriction and upgraded the shares to Neutral from Sell. He also boosted his price target for the shares to $41 from $37. The analyst says the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. He believes management action on business development, cost saving or moves to better monetize Pfizer's Established Product business are likely near-term drivers of the stock.
02/20/19
02/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) resumed with a Neutral from Sell at Citi with analyst Andrew Baum saying the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. 2. Transocean (RIG) and Diamond Offshore (DO) were upgraded to Overweight from Underweight at Barclays. 3. American Axle (AXL) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy citing progress with restructuring, GM's (GM) truck cycle, and balance sheet deleveraging. 4. Credit Suisse (CS) upgraded to Hold from Sell at Berenberg. 5. Ipsen (IPSEY) upgraded to Neutral from Sell at Goldman Sachs with analyst Diana Na citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
LEHM
02/26/19
NO CHANGE
LEHM
Galapagos weakness could be tied to Pfizer safety alert, says Barclays
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz. Competitor safety issues with higher dose JAK inhibitors was a major focus of Galapagos' post-earnings conference call last week, Barclays tells investors in a research note. Galapagos management, while limited in what it can say pending the data, seems to believe they can get both doses approved, Barclays contends. Further, the firm points out that the company has received no communication and sees no reason to conclude that the FDA has determined that thromboembolic events are a class effect of the JAKs. Shares of Galapagos are down 1.5%, or $1.45, to $97.28 in late morning trading.
LLY Eli Lilly
$115.20

-1.23 (-1.06%)

04/11/19
GUGG
04/11/19
DOWNGRADE
GUGG
Neutral
Eli Lilly downgraded to Neutral from Buy at Guggenheim
04/11/19
GUGG
04/11/19
DOWNGRADE
GUGG
Neutral
Guggenheim sees limited upside for Eli Lilly, downgrades to Neutral
As previously reported, Guggenheim analyst Seamus Fernandez downgraded Eli Lilly (LLY) to Neutral from Buy, stating that while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. Though he still thinks Eli Lilly has "the best long-term growth profile in US Pharma," that growth is the broad consensus view, said Fernandez, who removed his price target on the stock but estimates the fair value to be in the range of $125-$135 per share.
04/11/19
04/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Chipotle (CMG) downgraded to Hold from Buy at Jefferies with analyst Andrew Barish saying after rallying 65% in Q1, Chipotle's valuation is full and reflects improved visibility for "powerful" same-store-sales and margin drivers. 2. Eli Lilly (LLY) downgraded to Neutral from Buy at Guggenheim with analyst Seamus Fernandez saying while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. 3. U.S. Steel (X) downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners citing worse near-term U.S. market conditions than she anticipated. 4. Keurig Dr Pepper (KDP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying she sees a negative risk-reward despite a "well telegraphed" Q1 earnings beat on strong pricing at heritage Dr. Pepper Snapple. 5. Waste Management (WM) downgraded to Hold from Buy at Stifel with analyst Michael Hoffman saying he factors in incrementally weaker paper prices and the impact of wet weather. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."

TODAY'S FREE FLY STORIES

PINS

Pinterest

$26.69

0.68 (2.61%)

08:37
05/18/19
05/18
08:37
05/18/19
08:37
Periodicals
Pinterest committed 'cardinal sin' for newly public company, Barron's says »

Pinterest released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSHB

KushCo Holdings

$0.00

(0.00%)

08:32
05/18/19
05/18
08:32
05/18/19
08:32
Periodicals
Pot paraphernalia companies taking hit from tariffs, Barron's says »

The U.S.-China trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

JWN

Nordstrom

$37.09

0.16 (0.43%)

08:24
05/18/19
05/18
08:24
05/18/19
08:24
Periodicals
Nordstrom stock a 'can't miss bargain.' Barron's says »

Nordstrom remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

NTDOY

Nintendo

$0.00

(0.00%)

, TTWO

Take-Two

$106.76

-0.81 (-0.75%)

08:10
05/18/19
05/18
08:10
05/18/19
08:10
Periodicals
Take-Two 'winning the game,' Barron's says »

Videogame stocks are down…

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$106.76

-0.81 (-0.75%)

DIS

Disney

$135.04

-0.46 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 24

    Jun

  • 13

    Nov

TPR

Tapestry

$30.78

-0.56 (-1.79%)

, REGN

Regeneron

$304.81

-4.69 (-1.52%)

08:01
05/18/19
05/18
08:01
05/18/19
08:01
Periodicals
Regeneron, Tapestry among cheap stocks to ride out trade war, Barron's says »

Applied Materials (AMAT),…

TPR

Tapestry

$30.78

-0.56 (-1.79%)

REGN

Regeneron

$304.81

-4.69 (-1.52%)

SCHW

Charles Schwab

$43.21

-0.94 (-2.13%)

BWA

BorgWarner

$36.27

-0.375 (-1.02%)

AMAT

Applied Materials

$42.72

-1.56 (-3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 26

    Jun

  • 25

    Jul

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

, CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

07:25
05/18/19
05/18
07:25
05/18/19
07:25
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

SCHN

Schnitzer Steel

$23.16

0.42 (1.85%)

BRSS

Global Brass and Copper

$43.09

-0.01 (-0.02%)

LXFR

Luxfer

$25.41

-0.44 (-1.70%)

MTRN

Materion

$66.36

0.155 (0.23%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.84

-0.01 (-0.07%)

F

Ford

$10.29

-0.1 (-0.96%)

GM

General Motors

$37.00

-0.36 (-0.96%)

HMC

Honda

$25.64

-0.135 (-0.52%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.40

-1.44 (-1.20%)

VWAGY

Volkswagen

$0.00

(0.00%)

SHOO

Steven Madden

$31.49

-0.37 (-1.16%)

GIII

G-III Apparel

$31.82

-0.35 (-1.09%)

IIVI

II-VI

$32.66

-1.64 (-4.78%)

LITE

Lumentum

$46.30

-4.15 (-8.23%)

MU

Micron

$36.06

-1.37 (-3.66%)

WDC

Western Digital

$44.62

-0.82 (-1.80%)

COHR

Coherent

$121.28

-5.22 (-4.13%)

LASR

nLight

$21.21

-1.27 (-5.65%)

VECO

Veeco

$12.50

-0.25 (-1.96%)

NPTN

NeoPhotonics

$3.83

-0.7 (-15.45%)

AAPL

Apple

$188.97

-0.93 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 23

    Oct

WMT

Walmart

$100.88

-0.56 (-0.55%)

17:59
05/17/19
05/17
17:59
05/17/19
17:59
Hot Stocks
Walmart EVP Furner sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 15

    Aug

  • 13

    Nov

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

, REPYY

Repsol

$0.00

(0.00%)

17:56
05/17/19
05/17
17:56
05/17/19
17:56
Periodicals
Exxon Gulf of Mexico sale gets interest from Repsol, Ineos, Bloomberg says »

Exxon Mobil (XOM) has…

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

REPYY

Repsol

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

, SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

17:43
05/17/19
05/17
17:43
05/17/19
17:43
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

SLV

iShares Silver Trust

$13.52

-0.14 (-1.02%)

GLD

SPDR Gold Shares

$120.64

-0.86 (-0.71%)

FXE

Euro Currency Trust

$106.35

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

17:39
05/17/19
05/17
17:39
05/17/19
17:39
Periodicals
IMF's Lagarde: U.S.-China trade spat may be risk to global economy, Reuters says »

IMF managing director…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIG

Hartford Financial

$53.58

-0.02 (-0.04%)

17:34
05/17/19
05/17
17:34
05/17/19
17:34
Syndicate
Breaking Syndicate news story on Hartford Financial »

Hartford Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

AFH

Atlas Financial

$0.91

0.0225 (2.53%)

17:33
05/17/19
05/17
17:33
05/17/19
17:33
Hot Stocks
Atlas Financial receives filing delinquency notice from Nasdaq »

Atlas Financial received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Gas Partners

$30.60

-0.155 (-0.50%)

17:29
05/17/19
05/17
17:29
05/17/19
17:29
Syndicate
Breaking Syndicate news story on Western Gas Partners »

Western Gas Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.99

0.5 (0.14%)

17:24
05/17/19
05/17
17:24
05/17/19
17:24
Hot Stocks
Boeing awarded $163.91M Navy contract modification »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

LMT

Lockheed Martin

$338.10

-2.39 (-0.70%)

17:18
05/17/19
05/17
17:18
05/17/19
17:18
Hot Stocks
Lockheed Martin subsidiary awarded $1.13B Navy contract modification »

Sikorsky, a Lockheed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

COTY

Coty

$13.50

0.25 (1.89%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Coty exec Pieraccioni acquires 93,100 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMR

Alta Mesa Resources

$0.18

-0.0027 (-1.50%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Alta Mesa Resources receives noncompliance notification from Nasdaq »

Nasdaq notified Alta Mesa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$49.82

-0.03 (-0.06%)

17:06
05/17/19
05/17
17:06
05/17/19
17:06
Hot Stocks
New Jersey Resources' Trice sells 12,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

AHC

A.H. Belo

$3.82

-0.075 (-1.93%)

17:03
05/17/19
05/17
17:03
05/17/19
17:03
Hot Stocks
A.H. Belo sells former Dallas Morning News campus for $31.6M »

A. H. Belo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRA

Telaria

$8.56

0.2 (2.39%)

17:01
05/17/19
05/17
17:01
05/17/19
17:01
Hot Stocks
Telaria director Rossman sells 173K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 10

    Jun

HL

Hecla Mining

$1.53

0.015 (0.99%)

16:58
05/17/19
05/17
16:58
05/17/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNT

Innovate Biopharmaceuticals

$1.59

-0.095 (-5.65%)

16:57
05/17/19
05/17
16:57
05/17/19
16:57
Syndicate
Breaking Syndicate news story on Innovate Biopharmaceuticals »

Innovate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

JONE

Jones Energy

$0.00

(0.00%)

16:56
05/17/19
05/17
16:56
05/17/19
16:56
Hot Stocks
Jones Energy emerges from bankruptcy »

Jones Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPP

Hudson Pacific

$34.33

-0.15 (-0.44%)

16:44
05/17/19
05/17
16:44
05/17/19
16:44
Hot Stocks
Hudson Pacific CFO sells ~57K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

GLYC

GlycoMimetics

$12.42

-0.43 (-3.35%)

16:36
05/17/19
05/17
16:36
05/17/19
16:36
Syndicate
Breaking Syndicate news story on GlycoMimetics »

GlycoMimetics files $250M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.